Dr. Razak is the lead for Medical Oncology in The Princess Margaret/MSH’s Sarcoma Site Group. He is also the Interim Director representing Sinai Health Systems Oncology and Medical Genetics Programs. Dr. Razak completed his medical training in Ireland and his clinical training in Medical Oncology in the United Kingdom under the supervision of Dr. Hilary Calvert. He then completed a drug development fellowship at The Princess Margaret under the supervision of Dr. Lillian Siu.
Dr. Razak has a special interest in sarcoma and early drug development. His practice includes an active role in the Phase I Program at The Princess Margaret, developing and running drug clinical trials. He has been a recipient of the American Society of Clinical Oncology (ASCO) Merit Award, ASCO Young Investigator Award and was the inaugural recipient of the Mick Knighton-British Lung Foundation Mesothelioma Research Award, as well as the Canadian Sarcoma Cancer Foundation
Fellowship Award. Dr. Razak is appointed as a Clinician Investigator and Assistant Professor in the Department of Medicine, University of Toronto.
Dr. Abha Gupta received her MD at the University of Toronto. She completed her pediatrics residency at Yale New Haven Children’s Hospital (New Haven, CT) and Children’s Hospital of Eastern Ontario (Ottawa) before moving back to Toronto to complete her fellowship in paediatric hematology/oncology at The Hospital for Sick Children. To complement her training, Dr. Gupta completed a one-year fellowship in Adolescent and Young Adult Oncology with a focus on sarcoma at Princess Margaret Cancer Centre.
She is currently cross-appointed as a staff oncologist at both The Hospital for Sick Children (Solid Tumour Section) and Princess Margaret Cancer Center (Toronto Sarcoma Program). She is the Medical Director of the Adolescent and Young Adult Oncology Program at Princess Margaret and Medical Director of the Canadian Sarcoma Research and Clinical Collaboration (www.cansarcc.ca). She is also on the executive boards of the Connective Tissue Oncology Society, Sarcoma Section of the Canadian Cancer Trials Group, and Soft Tissue Sarcoma Committee of the Children’s Oncology Group.
Dr. Geoffrey Watson is a Staff Medical Oncologist at Mount Sinai Hospital and an Assistant Professor of Medicine at the University of Toronto. He completed his basic and specialized training in medical oncology in Dublin, Ireland.
Dr. Watson joined the Drug Development and Sarcoma Programs at the Princess Margaret Cancer Centre as a clinical research fellow in 2019. During this time he served as the Chief Fellow of the Division of Medical Oncology and Hematology, and was awarded with a Hold’em for Life Oncology Clinician Scientist Award in 2019, an ASCO Merit Award in 2020 and 2021 as well as the Novartis Oncology Young Canadian Investigator Award in 2020 and 2021.
Dr. Watson’s clinical focus is on the treatment of sarcoma and breast cancer. His academic interest is in patient reported outcomes and quality of life, and he also has an interest in teaching and education, particularly the evolving role of virtual education.
Dr Salawu trained in Medical Oncology at the Weston Park Cancer Centre, Sheffield, United Kingdom and completed a fellowship in sarcoma and early phase drug development and at Princess Margaret Cancer Centre, Toronto. Prior to this, he obtained Masters’ and Doctoral degrees from the University of Sheffield, United Kingdom, during which he studied structural and functional genomics of soft tissue sarcoma, disease models and biomarker development.
He is the recipient of a Novartis Oncology Young Canadian Investigator Award and the American Society of Clinical Oncology (ASCO) Merit and Young Investigator Awards. His current research interests are in translational oncology and biomarker development, clinical trials and ultra-rare sarcomas.
He is currently appointed as Assistant Professor of Medicine, University of Toronto and Staff Medical Oncologist at Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto.
Dr. Larry Park received his MD from the University of Kentucky (Lexington, KY). He completed his Internal Medicine residency at Case Western Reserve University/MetroHealth Medical Center (Cleveland, OH), followed by his Medical Oncology residency at McGill University (Montreal, QC). He subsequently completed a fellowship in Sarcoma, Genitourinary Oncology, and Drug Development at the Princess Margaret Cancer Centre, University of Toronto (Toronto, ON).
Dr. Park’s clinical practice focuses on the management of patients with sarcoma and genitourinary malignancies. His research interests include developmental therapeutics, biomarker-driven clinical trials, and understanding the molecular mechanisms underlying treatment response and resistance. He is particularly interested in integrating liquid biopsy technologies into clinical research to improve treatment selection and disease monitoring.
Dr. Park is appointed as a Clinician Investigator in the Division of Medical Oncology and Hematology and as an Assistant Professor of Medicine at the University of Toronto.
Back to Our Team